Skip To Main Content
Prateesh Varughese on Muck Rack

Prateesh Varughese

As seen in: ONCOLOGY journal, Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Prateesh

Contact Prateesh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HSD86 FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES

|
By Virginia Commonwealth, Roby Thomas, Dhaval Shah, Asit K. Paul, Deepak Kilari, Bogdana Schmidt, Alejandro Sanchez, Alejandro Sánchez, Rushir Choksi, John LI, Gino Cioffi, Steven W. Champaloux, Don Parris, Mike Gart, Brandon Wang, Prateesh Varughese, Jeffrey Scott, Manish Kohli, Anna Rui
| Value in Health Journal Verified
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Open in Who Shared View Duplicates (615) Issue with article?

25 Real-world BRCA1/2 Testing Patterns in HER2-Negative Early- Stage Breast Cancer (eBC) Patients

|
By Brandon Wang, Sandy English, Simon Blanc, Gieira S. Jones, Erin Alwon, Poras Dave, Prateesh Varughese, Arthur Sillah
| ONCOLOGY journal Verified
Background Clinical trials have demonstrated improved disease-free survival and overall survival in HER2-negative early-stage breast cancer patients with germline BRCA1/2 mutations who received adjuvant PARP inhibitors. It remains critical to assess BRCA1/2 testing patterns in clinical care to ensure that patients have access to all treatment options.
Open in Who Shared Issue with article?
See all 2 articles